Record Revenue and Growth
Achieved record revenue of $245.9 million for fiscal 2024, representing a 16% year-over-year growth. Adjusted EBITDA was $57.9 million, a 14% increase over last year.
Expansion and Customer Base Growth
Expanded to over 135 locations across 26 states with over 314,000 active patients. The customer base grew 10% year-over-year.
Increased Respiratory Resupply Setups
Respiratory resupply setups and deliveries increased to 480,000 for the year ended September 30, 2024, reflecting a growth of 21%.
Strong Recurring Revenue
Recurring revenue remained strong, exceeding 78% of total revenue in fiscal year 2024.
Positive Adjustments for Medicare and Medicaid
Centers for Medicare and Medicaid Services announced positive CPI adjustments for 2025 fee schedules, ranging from 2.4% to 3%.
Growing Sleep Business
GLP-1 medications have no negative impact on demand. Referral activity for new device setups remains steady, with replacement supply volumes strong.